ERBB2 and breast cancer: Although significant improvements in the invasive disease-free survival (iDFS) of HER2-negative BC patients receiving adjuvant olaparib have been reported, it could not improve the iDFS of HR-positive HER2-negative BC patients in the subgroup analysis, as reported by the OlympiA study [9].